![The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]](https://www.2minutemedicine.com/wp-content/uploads/2013/05/web-cover-classics-with-logo-medicine-BW-small-jpg-350x250.jpg){kind=logo}
5-day versus 10-day course of remdesivir in patients with severe COVID-19 [Classics Series]
This study summary is an excerpt from the book 2 Minute Medicine's The Classics in Medicine: Summaries of the Landmark ...
Tag: remdesivir
The ACTT-1: Remdesivir for the treatment of COVID-19 [Classics Series]
This study summary is an excerpt from the book 2 Minute Medicine's The Classics in Medicine: Summaries of the Landmark ...
Remdesivir does not reduce mortality in ventilated patients with COVID-19
1. No significant decrease in mortality risk was seen in ventilated patients with COVID-19 on remdesivir compared to control. 2. ...
Molnupiravir does not improve clinical outcomes in patients hospitalized with COVID-19
1. Patients hospitalized with COVID-19 receiving at least one dose of molnupiravir did not show reduced mortality compared to patients ...
#VisualAbstract: The use of COVID-19 convalescent plasma not beneficial to patients hospitalized with COVID-19
1. The use of COVID-19 convalescent plasma did not benefit patients hospitalized with COVID-19, assessed using the World Health Organization ...
5-day versus 10-day course of remdesivir in patients with severe COVID-19
1. Compared to patients who received remdesivir for 10 days, those in the 5-day group experienced no significant difference in ...
Remdesivir in adults with severe COVID-19
1. Adults with severe COVID-19 treated with remdesivir had numerically faster time to clinical improvement compared to controls, but the ...
#VisualAbstract: Compassionate Use of Remdesivir for Patients with Severe COVID-19
1. In this study, nearly 70% of patients who received remdesivir for compassionate use had an improvement in oxygen-support class ...
2 Minute Medicine Rewind May 4, 2020
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial 1. Adults with severe COVID-19 treated with remdesivir ...
Results from remdesivir compassionate use study for severe COVID-19
1. In this study, nearly 70% of patients who received remdesivir for compassionate use had an improvement in oxygen-support class ...